Progyny price to sales ratio PGNY

Market value divided by revenue over the last twelve months, since 2020.

Today, Oct 23, 2026: 1.7×
7-year median: 3.9×
Against its 7-year history: 27th; percentile: 0 is its lowest day, 100 its highest
7-year range: 1.0× to 14.8×
Peer median: 1.3×

Progyny's price to sales ratio is 1.7× as of Oct 23, 2026.

That is below its 7-year median of 3.9×, lower than on 73% of days in the last 7 years.

Over that time it ranged from 1.0× in Nov 2024 to 14.8× in Jun 2021.

The median for 10 hospital and care facility stocks of a similar size is 1.3×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.7×	1.0×	1.9×
2025	1.8×	1.3×	1.8×
2024	1.3×	1.0×	3.8×
2023	3.4×	2.8×	4.7×
2022	4.1×	4.1×	9.5×
2021	9.6×	8.9×	14.8×
2020	11.9×	6.5×	11.9×

Against its peers

Companies in Medical - Care Facilities nearest Progyny's size, closest first, today.

Company	Price to sales ratio
PGNYProgyny	1.7×
ADUSAddus HomeCare	1.5×
MDPediatrix Medical	1.2×
HCSGHealthcare Services	0.9×
ARDTArdent Health	0.3×
PRVAPrivia Health	1.2×
AVAHAveanna Healthcare	1.1×
PNTGPennant	1.3×
NHCNational Healthcare	2.4×
USPHU S Physical Therapy	1.6×
OMDAOmada Health	3.7×
Peer median	1.3×

Where Progyny ranks

#32of 45Hospital and care facility stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Progyny

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.